Skip to Main Content
Table I.

Clinical Characteristics of Breast Cancer Patients (n = 547)




Allele frequency

Clinical parameter

CCR5wt
CCR5Δ32
P (χ2)
Age <50 91.35 8.65 0.59 
 >50 92.46 7.53  
Menopausal status Pre-Peri 92.72 7.28 0.73 
 Post 91.96 8.04  
Histologic grade I-II 91.64 8.36 0.86 
 III 91.07 8.93  
Tumor size T1 92.82 7.18  
 T2 92.44 7.56  
 T3 92.04 7.95  
 T4 85.71 14.29 0.04 
Lymph node infiltration 92.41 7.58  
 1–3 93.08 6.91  
 4–9 92.96 7.04  
 >10 89.58 10.4 0.36 
Stage 92.02 7.97  
 II 92.62 7.38  
 III 89.24 10.76 0.22 
Estrogen receptor Neg 91.21 8.79 0.52 
 Pos 92.54 7.46  
Progesterone receptor Neg 91.63 8.37 0.76 
 Pos 92.32 7.68  
ErbB-2 Neg 92.87 7.13 0.62 
 Pos 91.48 8.52  
Angiogenin Neg 94.11 5.88 0.63 
 Pos 92.21 7.79  
p53 Neg 91.11 8.89  

 
Pos
 
94.11
 
5.89
 
0.1
 



Allele frequency

Clinical parameter

CCR5wt
CCR5Δ32
P (χ2)
Age <50 91.35 8.65 0.59 
 >50 92.46 7.53  
Menopausal status Pre-Peri 92.72 7.28 0.73 
 Post 91.96 8.04  
Histologic grade I-II 91.64 8.36 0.86 
 III 91.07 8.93  
Tumor size T1 92.82 7.18  
 T2 92.44 7.56  
 T3 92.04 7.95  
 T4 85.71 14.29 0.04 
Lymph node infiltration 92.41 7.58  
 1–3 93.08 6.91  
 4–9 92.96 7.04  
 >10 89.58 10.4 0.36 
Stage 92.02 7.97  
 II 92.62 7.38  
 III 89.24 10.76 0.22 
Estrogen receptor Neg 91.21 8.79 0.52 
 Pos 92.54 7.46  
Progesterone receptor Neg 91.63 8.37 0.76 
 Pos 92.32 7.68  
ErbB-2 Neg 92.87 7.13 0.62 
 Pos 91.48 8.52  
Angiogenin Neg 94.11 5.88 0.63 
 Pos 92.21 7.79  
p53 Neg 91.11 8.89  

 
Pos
 
94.11
 
5.89
 
0.1
 

Estrogen receptor+ defined as ≥10 fmol/mg, progesterone receptor+ as ≥20 fmol/mg (Abbott), ErbB-2+ as ≥15 HNU/μg (Oncogene Science), angiogenin+ as ≥5 ng/mg (R&D Systems), and p53+ defined by Western blot with pAb 181 (Oncogene Science) according to established standards.

Close Modal

or Create an Account

Close Modal
Close Modal